Karyopharm Therapeutics (KPTI) Change in Acquisitions & Divestments (2016 - 2025)
Karyopharm Therapeutics' Change in Acquisitions & Divestments history spans 11 years, with the latest figure at $5.0 million for Q4 2025.
- For Q4 2025, Change in Acquisitions & Divestments fell 69.23% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $43.4 million, down 71.91%, while the annual FY2025 figure was $43.4 million, 71.91% down from the prior year.
- Change in Acquisitions & Divestments reached $5.0 million in Q4 2025 per KPTI's latest filing, up from $4.8 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $69.0 million in Q1 2021 to a low of $4.8 million in Q3 2025.
- Average Change in Acquisitions & Divestments over 5 years is $34.0 million, with a median of $31.1 million recorded in 2021.
- Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 113.38% in 2023, then plummeted 83.01% in 2025.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $30.5 million in 2021, then grew by 4.34% to $31.8 million in 2022, then skyrocketed by 36.49% to $43.4 million in 2023, then tumbled by 62.56% to $16.2 million in 2024, then crashed by 69.23% to $5.0 million in 2025.
- Per Business Quant, the three most recent readings for KPTI's Change in Acquisitions & Divestments are $5.0 million (Q4 2025), $4.8 million (Q3 2025), and $18.3 million (Q2 2025).